TAT peptide (TFA)

• UNSPSC Description:

  TAT peptide (TFA) is a cell penetrating peptide (GRKKRRQRRRPQ) derived from the trans-activating transcriptional activator (Tat) from HIV-1[1][2].

• Target Antigen:

  HIV

• Type:

  Peptides

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/tat-peptide-tfa.html

• Purity:

  99.65

• Solubility:

  H2O : ≥ 50 mg/mL

• Smiles:

  OC(C(F)(F)F)=O.O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN

• Molecular Weight:

  1735.93

• References & Citations:

  [1]Orzáez M, et al. Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells toerlotinib/cell-cycle inhibitors combination treatment. Cell Death Dis. 2012 Oct 25;3:e415.|[2]Lou L, et al. Functionalized magnetic-fluorescent hybrid nanoparticles for cell labelling. Nanoscale. 2011 May;3(5):2315-23.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported